Annovis Bio Inc. Secures 18-Month NYSE Compliance Extension
TL;DR
Annovis Bio gains an 18-month extension from NYSE to meet listing requirements, offering investors a window to capitalize on its neurodegenerative disease therapies development.
Annovis Bio's compliance plan accepted by NYSE outlines specific milestones to regain listing standards, ensuring continued trading without operational disruptions.
Annovis Bio's work on therapies for Alzheimer’s and Parkinson’s promises to enhance patient quality of life by targeting multiple neurotoxic proteins.
Exploring Annovis Bio's innovative approach to neurodegeneration reveals a potential breakthrough in treating Alzheimer’s and Parkinson’s diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
Annovis Bio Inc. (NYSE: ANVS), a clinical-stage company focused on developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, has received an 18-month compliance extension from the New York Stock Exchange. This extension, effective from March 26, 2025, allows the company additional time to meet the NYSE's minimum market capitalization and stockholders' equity requirements. Annovis Bio's ability to continue trading on the NYSE during this period is contingent upon meeting specific milestones and adhering to other listing standards. The company emphasizes that this development does not affect its operational activities, business strategies, or reporting obligations to the Securities and Exchange Commission. For further details, the full press release can be accessed here.
Curated from InvestorBrandNetwork (IBN)
